DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.

Zongwang ZhangYanwei WuBing WuQing QiHeng LiHuimin LuChen FanChunlan FengJianping ZuoLili NiuWei Tang

Published in: Arthritis research & therapy (2019)

DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types and would be a potential drug for the treatment of systemic sclerosis.

Keyphrases

systemic sclerosis
interstitial lung disease
oxidative stress
mouse model
single cell
cell therapy
rheumatoid arthritis
stem cells
replacement therapy
human health
mesenchymal stem cells
bone marrow
smoking cessation